mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys
- PMID: 17353071
- DOI: 10.1016/j.neurobiolaging.2007.02.005
mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys
Abstract
Modulation of excessive glutamatergic transmission within the basal ganglia is considered as an alternative approach to reduce l-Dopa-induced dyskinesias (LIDs) in Parkinson's disease (PD). In this study receptor binding autoradiography of [3H]MPEP, a metabotropic glutamate receptor 5 (mGluR5) selective radioligand, was used to investigate possible changes in mGluR5 in the basal ganglia of l-Dopa-treated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) monkeys having developed LIDs compared to animals in which LIDs was prevented by adjunct treatments. LIDs were associated with an increase of mGluR5 specific binding in the posterior putamen and pallidum (+41% and +56%) compared to controls. By contrast, prevention of dyskinesias was associated with an important decrease of mGluR5 specific binding in these areas (-37% and -48%) compared with dyskinetic animals. Moreover, an upregulation (+34%) of mGluR5 receptor binding was seen in the anterior caudate nucleus of saline treated MPTP monkeys. This study is the first to provide evidence that enhanced mGluR5 specific binding in the posterior putamen and pallidum may contribute to the pathogenesis of LIDs in PD.
Similar articles
-
Basal ganglia group II metabotropic glutamate receptors specific binding in non-human primate model of L-Dopa-induced dyskinesias.Neuropharmacology. 2008 Feb;54(2):258-68. doi: 10.1016/j.neuropharm.2007.08.009. Epub 2007 Aug 16. Neuropharmacology. 2008. PMID: 18001807
-
Effect of L-Dopa on metabotropic glutamate receptor 5 in the brain of parkinsonian monkeys.J Neurochem. 2010 May;113(3):715-24. doi: 10.1111/j.1471-4159.2010.06635.x. Epub 2010 Feb 1. J Neurochem. 2010. PMID: 20132464
-
Changes in glutamate receptors in dyskinetic parkinsonian monkeys after unilateral subthalamotomy.J Neurosurg. 2015 Dec;123(6):1383-93. doi: 10.3171/2014.10.JNS141570. Epub 2015 May 1. J Neurosurg. 2015. PMID: 25932606
-
Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease.Prog Neurobiol. 2012 Jan;96(1):69-86. doi: 10.1016/j.pneurobio.2011.10.005. Epub 2011 Nov 3. Prog Neurobiol. 2012. PMID: 22075179 Review.
-
Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications.Prog Neurobiol. 2007 Dec;83(5):293-309. doi: 10.1016/j.pneurobio.2007.07.001. Epub 2007 Jul 27. Prog Neurobiol. 2007. PMID: 17826884 Review.
Cited by
-
Effects of 5-HT1A receptor stimulation on D1 receptor agonist-induced striatonigral activity and dyskinesia in hemiparkinsonian rats.ACS Chem Neurosci. 2013 May 15;4(5):747-60. doi: 10.1021/cn300234z. Epub 2013 Apr 1. ACS Chem Neurosci. 2013. PMID: 23496922 Free PMC article.
-
Neurotoxic Agent-Induced Injury in Neurodegenerative Disease Model: Focus on Involvement of Glutamate Receptors.Front Mol Neurosci. 2018 Aug 29;11:307. doi: 10.3389/fnmol.2018.00307. eCollection 2018. Front Mol Neurosci. 2018. PMID: 30210294 Free PMC article. Review.
-
Glutamate receptors as therapeutic targets for Parkinson's disease.CNS Neurol Disord Drug Targets. 2009 Dec;8(6):475-91. doi: 10.2174/187152709789824606. CNS Neurol Disord Drug Targets. 2009. PMID: 19702565 Free PMC article. Review.
-
Group 1 Metabotropic Glutamate Receptors in Neurological and Psychiatric Diseases: Mechanisms and Prospective.Neuroscientist. 2022 Oct;28(5):453-468. doi: 10.1177/10738584211021018. Epub 2021 Jun 4. Neuroscientist. 2022. PMID: 34088252 Free PMC article. Review.
-
Pathophysiological Mechanisms and Experimental Pharmacotherapy for L-Dopa-Induced Dyskinesia.J Exp Pharmacol. 2021 Apr 29;13:469-485. doi: 10.2147/JEP.S265282. eCollection 2021. J Exp Pharmacol. 2021. PMID: 33953618 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources